NCT07616063Not yet recruiting
Subjective Assessment of Spatial Orientation Abilities in Alzheimer's Disease
Evaluation Subjective Des CApacités d'Orientation sPatialE Dans la mAladie D'Alzheimer
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
Difficulty orienting oneself and finding one's way around the environment, also known as "topographical disorientation" (TD) or "spatial disorientation" (SD), is a common and often early symptom of Alzheimer's disease (AD) that affects people's independence and well-being. Being able to identify it is therefore crucial in order to provide appropriate support. It cannot be assessed using conventional psychometric tests due to its low ecological validity. Several subjective assessment scales have been created to screen for SD "spatial disorientation" and assess its functional and psychological impact. However, none of these scales have been translated and validated in French. As a result, DS is not assessed in routine clinical practice. Among these scales, the Wayfinding Questionnaire (WQ) explores three dimensions: spatial orientation, distance estimation, and spatial anxiety. This questionnaire has undergone psychometric validation studies in its original Dutch version for a population with mild post-stroke , and norms for the general population have been published. Our team translated this questionnaire into French (i.e., "Questionnaire d'Orientation Spatiale" (QOS)) and adapted it cross-culturally to preserve the qualities of the measurement. A "Caregiver" version was also created, taking into account the anosognosia known to occur in AD. Primary Objective : Evaluate the psychometric properties of the Spatial Orientation Questionnaire (SOSQ) (i.e., the French translation and adaptation of the Wayfinding Questionnaire) in assessing spatial orientation disorders in patients with Alzheimer's disease, in both its "patient" and "caregiver" versions. Secondary objective : Evaluate the acceptability of the Spatial Orientation Questionnaire (SOC) in its "patient" and "caregiver" versions.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 330 (estimated)
- First submitted
- 4 May 2026
- Start date
- 1 May 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Central Hospital, Nancy, France
- Diseases
- Alzheimer disease
- NCT number
- NCT07616063
What you commit to
- Study type: Observational
- Planned participants: 330
- From 1 May 2026 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1.
Other illness
- History of moderate or severe head trauma (with loss of consciousness).
- Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)
Other
- For all subjects:
- Adults subject to legal protection measures (guardianship, curatorship, judicial protection)
- Adults unable to give their consent
- Persons capable of giving consent but unable to read French
- Persons capable of giving consent but unable to write
- One of the members of the patient/caregiver dyad refusing to participate in the study.
- Patients (subgroup A1) and healthy control subjects (group C):
- Sensory or phasic deficit interfering with the task.
- Change in psychotropic treatment less than 48 hours before the tests
- Chronic alcoholism
- Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale)
Who the study is looking for
- For all subjects :
- Native French speakers
- Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale)
- Person affiliated with a social security system or beneficiary of such a system
- Patients (Subgroup A1) and healthy control subjects (Group C):
- Individuals who have received complete information about the clinical research organization and have signed their written informed consent
- Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate
- Patients (group A):
- Aged 55 to 85
- Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria)
- Score of 4 or less on the Hachinski Ischemic Scale
- Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination)
- In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for \> 15 days
- Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane
- Caregivers (group B):
- Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week)
- Healthy control subjects (group C):
- Aged 55 to 85
- Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane
- Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards
Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU (Centre Hospitalier Régionale Universitaire) Nancy Coordinator of this site? Confirm its status | Nancy | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.